Streetbeat News

Stock Prices

VIAV

Viavi Solutions (NASDAQ:VIAV) reported Q2 adjusted EPS of $0.11, surpassing the $0.09 estimate, and sales of $254.50M, exceeding the $251.00M estimate. However, this represents a decrease from the previous year's earnings and sales.

Portfolio Pulse from totan@benzinga.com

February 01, 2024 | 9:38 pm

DXC

DXC Technology has officially appointed Raul Fernandez as its President and CEO, effective immediately. Fernandez, who took on the role of Interim President and CEO in December 2023, has a history of leading successful companies and has been a member of DXC's Board of Directors since 2020. Following this appointment, the Board has halted its search for a new CEO.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 9:35 pm

EMN

Eastman Chemical (NYSE:EMN) reported Q4 2023 adjusted earnings per share (EPS) of $1.31, slightly above the analyst consensus estimate of $1.30. Quarterly sales were $2.21 billion, in line with expectations but representing a 7% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 9:35 pm

CLX

Clorox shares surged following the announcement of better-than-expected Q2 financial results and an upward revision of the FY24 adjusted EPS guidance, surpassing analyst estimates.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 9:33 pm

AMZN

COLM

COUR

DECK

EXPR

SKX

In Thursday's after-market session, several consumer discretionary stocks showed significant movement. Coursera, Express, Deckers Outdoor, and Amazon.com were among the gainers, with their stocks rising due to recent earnings reports. Conversely, Columbia Sportswear, Skechers USA, Brinker International, Beazer Homes USA, Aterian, and Envirotech Vehicles were among the losers, primarily due to their latest earnings releases.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 9:31 pm

ADAG

KPRX

MYMD

PXMD

In Thursday's after-market session, several healthcare stocks showed notable movements. MyMD Pharmaceuticals, PaxMedica, Oragenics, Lineage Cell Therapeutics, BioRestorative Therapies, and Codexis experienced gains, with increases ranging from 5.81% to 9.3%. Conversely, Kiora Pharmaceuticals, Cingulate, Adagene, Sharps Technology, Alzamend Neuro, and Redhill Biopharma saw declines between 6.48% and 10.6%. These movements reflect significant volatility within the healthcare sector, impacting the market value of these companies.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 9:31 pm

AAPL

Apple reported a significant increase in iPhone net sales for Q1 2024, reaching $69.702 billion compared to $43.805 billion in the previous period. This substantial growth indicates a strong demand for iPhones, potentially reflecting successful product launches or marketing strategies.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 9:31 pm

AUVI

EXPO

GWH

ROMA

VLRS

In Thursday's after-market session, several industrials stocks showed notable movements. Roma Green Finance (ROMA) led the gainers with a 23.1% increase, while Exponent (EXPO) led the losers with a 6.5% decrease following its Q4 earnings report. Other notable movers included ESS Tech (GWH), Singularity Future Tech (SGLY), and Controladora Vuela (VLRS) among the gainers, and Applied UV (AUVI), Royalty Management Holdings (RMCO), and Dragonfly Energy Holdings (DFLI) among the losers.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 9:31 pm

ASX

CCTG

EGHT

GEN

TEAM

In Thursday's after-market session, 12 Information Technology stocks showed significant movements. CCSC Technology led the gainers with a 64.1% increase, while 8x8 experienced the largest drop among the losers, declining by 13.1%. Notably, ASE Tech Holding Co's shares rose by 4.93% following their Q4 earnings report, and both Gen Digital and Atlassian saw declines after their Q3 and Q2 earnings reports, respectively.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 9:31 pm

AAPL

Apple Inc. (AAPL) reported Q1 2024 adjusted earnings per share (EPS) of $2.18, surpassing the consensus estimate of $2.10 by 3.81%. Quarterly sales reached $119.60 billion, exceeding expectations of $117.91 billion by 1.43% and marking a 2.09% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 9:30 pm